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A super gene expression system 
enhances the anti-glioma effects of 
adenovirus-mediated REIC/Dkk-3 
gene therapy
Tetsuo Oka1, Kazuhiko Kurozumi1, Yosuke Shimazu1, Tomotsugu Ichikawa1, Joji Ishida1, 
Yoshihiro Otani1, Toshihiko Shimizu1, Yusuke Tomita1, Masakiyo Sakaguchi2, 
Masami Watanabe3, Yasutomo Nasu4, Hiromi Kumon4 & Isao Date1
Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) is a tumor suppressor and 
therapeutic gene in many human cancers. Recently, an adenovirus REIC vector with the super gene 
expression system (Ad-SGE-REIC) was developed to increase REIC/Dkk-3 expression and enhance 
therapeutic effects compared with the conventional adenoviral vector (Ad-CAG-REIC). In this study, 
we investigated the in vitro and in vivo effects of Ad-SGE-REIC on malignant glioma. In U87ΔEGFR and 
GL261 glioma cells, western blotting confirmed that robust upregulation of REIC/Dkk-3 expression 
occurred in Ad-SGE-REIC-transduced cells, most notably after transduction at a multiplicity of 
infection of 10. Cytotoxicity assays showed that Ad-SGE-REIC resulted in a time-dependent and 
significant reduction in the number of malignant glioma cells attaching to the bottom of culture wells. 
Xenograft and syngeneic mouse intracranial glioma models treated with Ad-SGE-REIC had significantly 
longer survival than those treated with the control vector Ad-LacZ or with Ad-CAG-REIC. This study 
demonstrated the anti-glioma effect of Ad-SGE-REIC, which may represent a promising strategy for the 
treatment of malignant glioma.
Malignant glioma is the most frequent type of primary brain tumor in adults. Glioblastoma, which is highly 
malignant, is characterized by marked neovascularity, rapid cell proliferation, infiltrative cell migration, and 
extensive necrosis1. The median survival of patients treated aggressively for glioblastoma is approximately 
14.6 months2. Currently, several new therapeutic agents, including various molecular targeted drugs, are being 
developed and evaluated in clinical trials.
Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) was identified as a gene whose expres-
sion is reduced in a variety of human cancer cells3–6. Adenovirus-mediated REIC/Dkk-3 (Ad-REIC) overexpres-
sion acts via c-Jun-NH2-kinase (JNK) and c-Jun5,7 and via endoplasmic reticulum (ER) stress6 to induce apoptosis 
in malignant mesothelioma and in prostate and testicular cancer cells, but not in non-cancer cells. Ad-REIC treat-
ment also inhibits the expression of Id-1, which influences cell cycle progression and has an anti-apoptotic effect8.
REIC/Dkk-3 regulates the growth and survival of glioma cells by caspase-dependent and -independent mech-
anisms via modification of the Wnt signaling pathway9. Using western blot analysis, we previously confirmed that 
REIC/Dkk-3 protein expression was reduced in malignant glioma cell lines10. Furthermore, increasing REIC/
Dkk-3 expression with an adenovirus vector led to a marked increase in the number of TUNEL-positive cells. 
The REIC/Dkk-3 gene regulates cell growth through caspase-dependent apoptosis, in particular, via caspase-9. 
Moreover, increasing REIC/Dkk-3 expression decreases β -catenin expression. These findings suggest that intra-
cellular overexpression of REIC/Dkk-3 plays a distinct role in apoptosis induction and anti-oncogenic activity. 
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However, there are only a few reports on the immunological reaction to secretory or exogenous REIC/Dkk-3 
protein11–13.
Gene therapy-based approaches often require high levels of gene expression and protein products14–17. 
We developed a novel adenoviral vector expressing REIC/Dkk-3, based on the cytomegalovirus (CMV) 
promoter-driven super gene expression system (Ad-SGE-REIC), by inserting the triple translational enhancer 
sequences of human telomerase reverse transcriptase (hTERT), Simian virus 40 (SV40), and CMV, downstream 
of the bovine growth hormone polyadenylation (BGH polyA) sequence. This gene expression cassette was named 
the super gene expression (SGE) system18. Because the CMV promoter-SGE system facilitates more potent gene 
expression, Ad-SGE-REIC is superior to conventional adenoviral systems with respect to REIC protein expres-
sion and therapeutic effects in prostate, renal, and cervical cancer and in malignant mesothelioma.
In this study, we compared Ad-SGE-REIC with a conventional Ad-REIC vector and evaluated the anti-glioma 
effect of Ad-SGE-REIC against malignant glioma. We further tested the effect of the activated immune system in 
a syngeneic mouse glioma model.
Results
Overexpression of REIC/Dkk-3 protein with Ad-SGE-REIC versus Ad-CAG-REIC. To examine 
the potential of REIC/Dkk-3 as a tool for targeted gene-based therapy, REIC/Dkk-3 was overexpressed using 
Ad-SGE-REIC in comparison with Ad-CAG-REIC. An adenoviral vector carrying the LacZ gene with a CAG 
promoter (Ad-LacZ) was used as the control. These adenoviral vectors were generated using replication-defective 
adenoviruses of serotype 5. REIC/Dkk-3 protein levels in U87Δ EGFR and GL261 glioma cells were evaluated at 
36 h after treatment with Ad-CAG-REIC or Ad-SGE-REIC. Robust upregulation of REIC/Dkk-3 expression was 
observed in the Ad-SGE-REIC-transduced cells at a multiplicity of infection (MOI) of 10 (Fig. 1).
Cytotoxic effect of Ad-SGE-REIC compared with Ad-CAG-REIC. Initially, glioma cells were infected 
with adenovirus, the adenovirus-containing media were aspirated at 3 h after infection, and the cells were then 
incubated in fresh media. The in vitro cytotoxic effect of Ad-REIC on glioma cells was investigated. U87Δ EGFR 
and GL261 cell lines were incubated with Ad-LacZ, Ad-CAG-REIC, or Ad-SGE-REIC at an MOI of 10 for the 
Figure 1. Protein expression of REIC/Dkk-3 in U87ΔEGFR and GL261 glioma cells after treatment with Ad-
SGE-REIC or Ad-CAG-REIC. U87Δ EGFR and GL261 glioma cells were infected with Ad-SGE-REIC or Ad-CAG-
REIC at an MOI of 10. (A) In U87Δ EGFR glioma cells, the increase in expression levels of REIC/Dkk-3 protein was 
greater after Ad-SGE-REIC treatment than after Ad-CAG-REIC treatment. (B) Quantification of the expression ratio 
(average expression levels: Ad-CAG-REIC; 0.93, Ad-SGE-REIC; 3.1) (n = 4). The protein band density was calculated 
using ImageJ software. P < 0.001. (C) In GL261 glioma cells, the increase in expression levels of REIC/Dkk-3 protein 
was greater after treatment with Ad-SGE-REIC than with Ad-CAG-REIC. (D) Quantification of the expression ratio 
(average expression levels: Ad-CAG-REIC; 0.25, Ad-SGE-REIC; 1.3) (n = 4). The protein band density was calculated 
using ImageJ software. P = 0.005. Data are shown as the mean ± SD.
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indicated times. The proliferation rates of both types of malignant glioma cells were time-dependently and more 
substantially reduced by Ad-SGE-REIC relative to Ad-CAG-REIC and Ad-LacZ (Fig. 2).
Cytotoxicity of Ad-SGE-REIC against normal human astrocytes. The in vitro cytotoxic effect of 
Ad-REIC on normal human astrocyte (NHA) cells was investigated. Incubation with Ad-LacZ, Ad-CAG-REIC, 
or Ad-SGE-REIC at an MOI of 10 for the indicated time did not alter the proliferation rate of NHA cells (Fig. 3).
Caspase expression, ER stress, and β-catenin degradation by REIC/Dkk-3 in malignant glioma 
cells. U87Δ EGFR glioma cells were treated with Ad-LacZ, Ad-CAG-REIC, or Ad-SGE-REIC at an MOI of 
10. At 36 h after infection, glioma cells were harvested. Western blot analysis revealed increased expressions of ER 
stress marker molecules Bip, phosphorylated IRE1α , and phosphorylated SAPK/JNK in Ad-SGE-REIC-infected 
cells compared with those in Ad-CAG-REIC- and Ad-LacZ-infected cells (Fig. 4).
The Wnt signaling pathway additionally regulates cell survival by inhibition of proteasome-dependent pro-
teolysis of β -catenin. Therefore, we evaluated the impact of Ad-LacZ, Ad-CAG-REIC, and Ad-SGE-REIC treat-
ment on β -catenin expression in malignant glioma cells. β -catenin protein levels were more potently reduced by 
Ad-SGE-REIC treatment than by Ad-CAG-REIC treatment.
Moreover, the activity of caspase-9 was evaluated in U87Δ EGFR cells. The cleaved form of caspase-9 expres-
sion was also increased in cells treated with Ad-SGE-REIC compared with those treated with Ad-CAG-REIC or 
Ad-LacZ (Fig. 5).
Therapeutic efficacy of Ad-SGE-REIC in xenograft mouse models and a syngeneic model. The 
anti-tumor effect of Ad-CAG-REIC and Ad-SGE-REIC was tested in mice bearing intracerebral glioma 
(U87Δ EGFR or GL261) and a syngeneic model (GL261). In all experiments, mice were injected with 3.6 × 107 
plaque-forming units (pfu) of adenovirus. Kaplan-Meier curves were used to analyze the survival time of the 
U87Δ EGFR mouse glioma model after treatment with Ad-LacZ, Ad-CAG-REIC, or Ad-SGE-REIC. The 
median survival time was longer in mice treated with Ad-SGE-REIC than with Ad-LacZ (22 and 18 days, 
respectively; P = 0.0038; Fig. 6A). Median survival was also longer in mice treated with Ad-SGE-REIC than 
with Ad-CAG-REIC (22 and 19 days, respectively; P = 0.0107; Fig. 6A). In the GL261 mouse glioma model, the 
median survival time was also significantly longer in mice treated with Ad-SGE-REIC than with Ad-LacZ (41 and 
33 days, respectively; P = 0.0257; Fig. 6B).
Figure 2. Cytotoxicity after Ad-SGE-REIC treatment in glioma cell lines. U87Δ EGFR (A,C) and GL261 
(B,D) glioma cells were infected with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ at an MOI of 10. Cell viability 
was examined 24, 48, and 72 h after infection. In cytotoxicity assays, the proliferation rate of malignant glioma 
cells was reduced in a time-dependent manner after treatment with Ad-SGE-REIC and the effect was stronger 
compared with that of Ad-CAG-REIC (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001).
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In the GL261 syngeneic model, the median survival time of mice treated with Ad-CAG-REIC was significantly 
longer than that of those treated with Ad-LacZ (47 and 36 days, respectively; P = 0.024; Fig. 6C). The median 
survival time of mice treated with Ad-SGE-REIC was also significantly longer than that of those treated with 
Ad-LacZ (103 and 36 days, respectively; P = 0.004; Fig. 6C).
Infection with Ad-REIC induces lymphocyte and dendritic cell infiltration into glioma. 
Immunological reactions to Ad-REIC were investigated by histological evaluation of GL261 gliomas at 21 
days after viral infection. Few CD8- and CD11c-positive cells had infiltrated the tumor specimens treated with 
Ad-LacZ (Figs 7 and 8). In stark contrast, obvious infiltration of both CD8- and CD11c-positive cells was detected 
in tumors treated with Ad-SGE-REIC or Ad-CAG-REIC (Figs 7 and 8). Infiltration of CD8- and CD11c-positive 
cells was significantly greater in tumors treated with Ad-SGE-REIC relative to those treated with Ad-CAG-REIC 
(P < 0.0001).
Discussion
Summary of results. This study focused on the anti-glioma activity of Ad-SGE-REIC, a novel adenoviral 
vector that produces higher protein expression and a superior therapeutic effect compared with the conventional 
system (Ad-CAG-REIC). REIC/Dkk-3 expression was upregulated in Ad-SGE-REIC-transduced glioma cells, 
and the most prominent effect was obtained after transduction at 10 MOI. In cytotoxicity assays, Ad-SGE-REIC 
time-dependently reduced the number of viable malignant glioma cells. In xenograft and syngeneic intracranial 
glioma models, Ad-SGE-REIC was associated with significantly longer survival than Ad-LacZ or Ad-CAG-REIC. 
Infiltration of CD8- and CD11c-positive cells was significantly greater in syngeneic gliomas treated with Ad-SGE-
REIC than in those treated with Ad-CAG-REIC.
Effects of Ad-REIC on glioma. Expression levels of REIC/Dkk-3 mRNA and protein are downregulated 
in malignant glioma cell lines10. Mizobuchi et al. reported that overexpression of REIC/Dkk-3 with a plasmid 
vector induced apoptosis in malignant glioma cells9. Similarly, we previously found that enhancing REIC/Dkk-3 
expression with an adenoviral vector led to a marked increase in the number of TUNEL-positive cells. Our data 
indicated that levels of the activated form of caspase-9 were significantly higher in glioma cells treated with 
Ad-SGE-REIC than in those treated with Ad-CAG-REIC and control.
Moreover, the expressions of Bip, phosphorylated IRE1α , and phosphorylated SAPK/JNK were increased 
in Ad-SGE-REIC-infected cells compared with Ad-CAG-REIC- and Ad-LacZ-infected cells. This result indi-
cated that ER stress was strongly evoked by Ad-SGE-REIC.  ER stress was also found to be evoked by enhanced 
REIC/Dkk-3 expression in malignant mesothelioma and in prostate and testicular cancer cells6,19. Additionally, 
expression levels of β -catenin, a key element of the Wnt signaling pathway, declined in parallel with the increase 
in REIC/Dkk-3 expression. Wnt signaling inhibits the release of cytochrome C and the subsequent activation of 
caspase-9 induced by apoptotic stimuli20.
Ad-SGE-REIC. Watanabe et al. found that insertion of the triple translational enhancer sequences of hTERT, 
SV40, and CMV downstream of the BGH polyA sequence yielded the most potent gene expression18. The hTERT 
promoter/enhancer is well-characterized and has been frequently used for cancer-specific gene expression21–24. 
Several studies have demonstrated increased gene expression by insertion of the SV40 enhancer downstream of 
Figure 3. Cytotoxicity after Ad-SGE-REIC treatment in normal human astrocytes (NHA). NHA cells were 
infected with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ at a MOI of 10. Cell viability was examined 24, 48, 
and 72 h after infection. In cytotoxicity assays, the proliferation rates of NHAs were not significantly different 
after treatment with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ.
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polyA sequences15–17. The CMV enhancer is used in the CMV early enhancer/chicken β -actin promoter (CAG 
promoter), which is known to improve gene expression in various cell types and tissues16. Because this novel 
gene expression system using triple enhancers significantly increases the expression of the gene(s) of interest in 
comparison with conventional systems using the strong CMV promoter, we termed this novel gene expression 
cassette, the SGE system.
Efficacy of Ad-SGE-REIC. In various types of human cancer cell, the induction of apoptosis is significantly 
increased by transduction of Ad-SGE-REIC compared with conventional Ad-REIC vectors. Furthermore, the 
inhibitory effects of Ad-REIC treatment on tumor growth have been analyzed in xenograft models. In both mouse 
renal cell carcinoma and human prostate cancer models, strong suppression of tumor growth was observed in 
the Ad-SGE-REIC-treated groups relative to the other treatment groups18. Thus, the novel SGE system signifi-
cantly augments the anti-tumor effects of Ad-REIC in mouse xenograft models, and the Ad-SGE-REIC vector 
was superior to the conventional Ad-CMV-REIC and Ad-CAG-REIC vectors in terms of the efficacy of in vivo 
intratumoral gene therapy. The present findings demonstrated that in xenograft models the survival time of mice 
treated with Ad-SGE-REIC was significantly longer than that of those treated with Ad-LacZ or Ad-CAG-REIC. 
Furthermore, in a syngeneic model, the survival time of mice treated with Ad-SGE-REIC was vastly longer than 
that of those treated with conventional Ad-REIC.
Anti-tumor effect of Ad-SGE-REIC in the syngeneic model. In the GL261 syngeneic mouse glioma 
model, mice treated with Ad-CAG-REIC survived significantly longer than those treated with Ad-LacZ. 
Infiltration of CD8- and CD11c-positive cells was significantly greater in tumors treated with Ad-CAG-REIC 
than in those treated with Ad-LacZ. In another study, intratumoral administration of REIC/Dkk-3 protein also 
significantly suppressed tumor growth, which was linked to accumulation of CD8- and CD11c-postiive cells 
(killer T marker and dendritic cells, respectively), and enhanced the anti-cancer cytolytic activity of splenocytes11. 
Furthermore, the survival time of mice treated with Ad-SGE-REIC was significantly longer than that of those 
Figure 4. ER stress in U87ΔEGFR glioma cells after treatment with Ad-SGE-REIC. U87Δ EGFR cells 
were infected with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ at a MOI of 10. Immunoblot analysis showed 
that levels of BiP, phosphorylated IRE1α , SAPK/JNK, and phosphorylated SAPK/JNK were increased in the 
U87Δ EGFR cell line following treatment with Ad-SGE-REIC. (B) Quantification of the expression ratio of 
BiP (average expression levels: Ad-CAG-REIC; 0.72, Ad-SGE-REIC; 2.27) (n = 4). (C) Quantification of the 
expression ratio of pIRE1α (average expression levels: Ad-CAG-REIC; 0.96, Ad-SGE-REIC; 2.01) (n = 4). (D) 
Quantification of the expression ratio of SAPK/JNK (average expression levels: Ad-CAG-REIC; 1.58, Ad-SGE-
REIC; 1.62) (n = 4). (E) Quantification of the expression ratio of pSAPK/JNK (average expression levels: Ad-
CAG-REIC; 1.11, Ad-SGE-REIC; 1.90) (n = 4). Protein band density was calculated using ImageJ software. Data 
are shown as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.0001, ****p < 0.0005.
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treated with Ad-LacZ. Both CD8- and CD11c-positive cells displayed significantly greater infiltration into tumors 
treated with Ad-SGE-REIC than into those treated with Ad-CAG-REIC. Therefore, the in vivo anti-tumor effect 
of REIC/Dkk-3 protein largely depends on the induction of enhanced systemic anti-cancer immunity.
Future direction. Ad-REIC is being developed for evaluation in clinical trials. At the time of publication, a 
first-in-human, phase I/IIa clinical trial of in situ Ad-REIC gene therapy for prostate cancer was done at Okayama 
University Hospital25,26. In addition, a phase I clinical trial of Ad-SGE-REIC for malignant mesothelioma was 
initiated in September 2015. According to the findings of these trials, a clinical trial of Ad-SGE-REIC for the 
treatment of glioma will be planned. Moreover, we showed that integrin antagonist cilengitide augmented the 
therapeutic effect of Ad-REIC gene therapy for malignant glioma10. Several preclinical studies have shown that 
cilengitide has an enhanced antitumor effect when administered in combinatorial therapeutic regimens27–33. 
Furthermore, combination therapy of Ad-REIC with chemotherapy, molecular targeted therapy, and immuno-
therapy should also be evaluated.
In conclusion, we demonstrated the anti-glioma effect of the Ad-SGE-REIC. Our results indicated that 
Ad-SGE-REIC has potential as a strategy for the treatment of malignant glioma.
Materials and Methods
Cell lines. The glioma cell lines U87Δ EGFR and GL261 were seeded on tissue culture dishes (BD Falcon, 
Franklin Lakes, NJ, USA) and cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal 
bovine serum, 100 U penicillin, and 0.1 mg/ml of streptomycin. GL261 cells were provided by Dr. A. Natsume, 
Nagoya University (Nagoya, Japan). NHA cells were purchased from Takara Bio Inc. (Shiga, Japan).
Adenovirus vector carrying SGE-REIC/Dkk-3. For Ad-REIC under the control of the CAG promoter, 
the full-length human REIC/Dkk-3 gene was inserted into the cosmid vector pAxCAwt and then transferred into 
an adenoviral vector using the COS-TPC method (Takara Bio). The SGE system was made by inserting the triple 
translational enhancer sequences of human telomerase reverse transcriptase (hTERT), Simian virus 40 (SV40), 
Figure 5. Expression of β-catenin in the nucleus of U87ΔEGFR glioma cells and caspase-9 expression in 
U87ΔEGFR glioma cells after Ad-SGE-REIC treatment. (A) U87Δ EGFR cells were infected with Ad-SGE-
REIC, Ad-CAG-REIC, or Ad-LacZ at an MOI of 10. A reduction in β -catenin expression occurred in parallel 
with increased expression of REIC/Dkk-3 (n = 4). (B) Quantification of the expression ratio of β -catenin (average 
expression levels: Ad-CAG-REIC; 0.22, Ad-SGE-REIC; 0.11) (n = 4). (C) Cleaved caspase-9 expression increased 
following treatment with Ad-SGE-REIC compared with Ad-CAG-REIC or Ad-LacZ. (D) Quantification of 
the expression ratio of caspase-9 (average expression levels: Ad-CAG-REIC; 0.51, Ad-SGE-REIC; 0.63) (n = 4). 
(E) Quantification of the expression ratio of cleaved caspase-9 (average expression levels: Ad-CAG-REIC; 0.30, 
Ad-SGE-REIC; 0.50) (n = 4). Protein band density was calculated using ImageJ software. Data are shown as the 
mean ± SD. *p < 0.0001, **p = 0.001, ***p < 0.05, ****p < 0.01.
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and cytomegalovirus (CMV) downstream of the BGH polyA sequence. An adenoviral vector carrying the LacZ 
gene with a CAG promoter (Ad-LacZ) was used as the control. These adenoviral vectors were generated using 
replication-defective adenoviruses of serotype 518.
Cytotoxicity assay. Cells were cultured in flat-bottomed six-well dishes at a concentration of 4.0 × 105 cells/well. 
The cells were infected with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ at an MOI of 10.
At 24, 48 and 72 h later, Cell viability was examined. The number of cells attached to the bottom of each culture 
well was determined in three different wells using a Z2 Coulter Counter (Beckman Coulter, Brea, CA, USA).
Western blot analysis. After cell culture in flat-bottomed six-well dishes, the media were aspirated, the 
dishes were washed twice in phosphate-buffered saline, and the cells were lysed in 1% sodium dodecyl sulfate. The 
lysates were sonicated for analyzing whole-cell proteins. Nuclear proteins were isolated using an NE-PER Nuclear 
and Cytoplasmic Extraction Kit (Thermo Scientific, Waltham, MA, USA), according to the manufacturer’s 
instructions. Extracted protein samples were separated by gel electrophoresis and transferred onto polyvinylidene 
difluoride membranes. After blocking in 5% skim milk, the membranes were incubated overnight with primary 
antibodies at 4 °C. The membranes were washed with Tris-buffered saline-Tween 20 (TBST), incubated with 
secondary antibodies at room temperature for 1 h, and rinsed with TBST. Signals were visualized using the ECL 
Prime Western Blotting Detection System (GE Healthcare Life Sciences, Buckinghamshire, UK). The primary 
antibodies, mouse anti-human REIC/DKK-3 (provided by the Department of Urology, Okayama University, 
Okayama, Japan), rabbit anti-human Bip, mouse anti-human β -catenin, rabbit anti-human caspase-9, rabbit 
anti-human SAPK/JNK, mouse anti-human phosphorylated SAPK/JNK, TATA-binding protein (TBP) (Cell 
Signaling Technology, Danvers, MA, USA), and rabbit anti-human phosphorylated IRE1α (Novus Biochemicals, 
Littleton, CO, USA) were diluted 1:1000 in TBST, and β -actin antibody (Sigma, St Louis, MO, USA) was diluted 
Figure 6. Kaplan-Meier survival curves of the U87ΔEGFR and GL261 mouse glioma models and of the 
GL261 mouse syngeneic models treated with Ad-SGE-REIC or Ad-CAG-REIC. (A) At 7 days after U87Δ 
EGFR cell implantation to BALB/c mice, mice were treated with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ 
(3.6 × 107 pfu) by direct intratumoral injection. The survival time of mice treated with Ad-SGE-REIC was 
significantly longer than that of those treated with Ad-LacZ or Ad-CAG-REIC (median survival = 22, 18, and 19 
days, respectively; P = 0.0038 and P = 0.0107) (n = 10 each group). (B) At 7 days after GL261 cell implantation 
to BALB/c mice, mice were treated with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-LacZ (3.6 × 107 pfu) by direct 
intratumoral injection. The survival time of mice treated with Ad-SGE-REIC was significantly longer than that 
of those treated with Ad-LacZ (median survival = 41 and 33 days; P = 0.0257) (n = 10 each group). (C) At 7 days 
after GL261 cell implantation to C57BL/6N mice, mice were treated with Ad-SGE-REIC, Ad-CAG-REIC, or Ad-
LacZ (3.6 × 107 pfu) by direct intratumoral injection. The survival time of mice treated with Ad-CAG-REIC was 
significantly longer than that of those treated with Ad-LacZ (median survival = 47 and 36 days, respectively; 
P = 0.024). The survival time of mice treated with Ad-SGE-REIC was significantly longer than that of those 
treated with Ad-LacZ (median survival = 103 and 36 days, respectively; P = 0.004) (n = 10 each group).
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1:5000 in TBST. The secondary antibody horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG 
(Cell Signaling Technology) was diluted 1:6000 (REIC/Dkk-3, caspase-9, and β -actin) or 1:2000 (β -catenin, BiP, 
pIRE1α , SAPK/JNK, pSAPK/JNK, and TATA-binding protein) in TBST.
Ethics and animal use statement. This study was conducted in strict accordance to the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals in Japan. Animals were housed at 25 °C with 12-h 
light/dark cycles and free access to water and standard rodent chow in the Department of Animal Resources of 
Okayama University. All procedures and animal protocols were approved by the Committee on the Ethics of 
Animal Experimentation at Okayama University (Permit No. OKU-2014264). All surgery was performed under 
general anesthesia with ketamine/pentobarbital, and all efforts were made to minimize animal suffering.
In vivo experiments. Before implantation, 85 to 90% confluent U87Δ EGFR cells or GL261 cells were 
trypsinized and centrifuged at 100 g for 5 min; the cell pellet was resuspended in phosphate-buffered saline, and 
the cell concentration was adjusted to 1.0 × 105 cells/μ l. For the xenograft models, U87Δ EGFR or GL261 cells (2 μ l) 
were injected into 6-week-old female BALB/c nude mice (CLEA Japan Inc., Tokyo, Japan). For the syngeneic 
model, GL261 cells (2 μ l) were injected into 6-week-old female C57BL/6N mice. The mice were anesthetized and 
placed in stereotactic frames (Narishige, Tokyo, Japan) with their skulls exposed. Tumor cells were injected with 
a Hamilton syringe (Hamilton, Reno, NV, USA) into the right frontal lobe (3 mm lateral to the midline, 1 mm 
posterior to the coronal suture, 3 mm depth from the dura), and the syringe was withdrawn slowly after 5 min to 
prevent reflux. The skulls were then cleaned, and the incision was sutured. At 7 days after tumor inoculation, all 
mice bearing brain tumors were reanesthetized and stereotactically injected with Ad-SGE-REIC, Ad-CAG-REIC, 
or Ad-LacZ at the tumor inoculation site using the same coordinates.
Histological procedures. For the detection of CD8- or CD11c-positive cell infiltration into gliomas after 
Ad-REIC treatment, GL261 glioma cells were implanted, then 3.6 × 107 pfu of Ad-SGE-REIC, Ad-CAG-REIC, 
or Ad-LacZ was injected intratumorally 7 days after tumor inoculation. Mice were sacrificed, and their excised 
brains were embedded in paraffin at 28 days after tumor inoculation. Immunohistochemical staining was per-
formed after samples were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol. 
Sections with a thickness of 4 μ m were incubated in 0.3% H2O2 (30 min) and then autoclaved for 15 min at 
121 °C in 10 mM sodium citrate buffer, pH 6.0. Immunohistochemical staining for CD8 was performed with 
mouse monoclonal CD8 antibody (1:50 dilution, no. 550281, BD Pharmingen, San Diego, CA, USA). The Dako 
Cytomation Envision+ System-HRP Kit was then applied according to the manufacturer’s protocol (Dako 
Figure 7. Histological analysis of glioma treated with Ad-REIC. CD8-positive killer T lymphocyte 
infiltration into gliomas treated with Ad-SGE-REIC and with Ad-CAG-REIC was detected by monoclonal 
antibody staining. A significant increase in CD8-positive cells was detected in gliomas treated with Ad-SGE-
REIC compared with Ad-CAG-REIC (*P < 0.0001).
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Cytomation, Carpentaria, CA, USA). After washing in PBS, the sections were counterstained with hematoxy-
lin. Immunohistochemical staining for CD11c was performed with mouse monoclonal anti-CD11c antibody 
(no. 550375, BD Pharmingen) using the same method.
Statistical analyses. Data on protein expression obtained by western blotting were analyzed using Student’s 
t-test. The proliferation rates obtained from cytotoxicity assays were analyzed using one-way analysis of variance 
(ANOVA) followed by Tukey’s post hoc test. Kaplan-Meier survival curves were compared using the log-rank test. 
The number of CD8- and CD11c-positive cells/field was analyzed using one-way ANOVA followed by Tukey’s 
post hoc test. Statistical analyses were performed using SPSS statistical software (version 20; SPSS, Inc., Chicago, 
IL, USA). P-values < 0.05 were considered statistically significant.
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